Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders.
Antibody index
Autoimmune
CMV
EBV
HSV
Psychosis
SSD
Schizophrenia
Toxoplasmosis
Journal
Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
21
04
2022
accepted:
30
06
2022
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
3
8
2022
Statut:
epublish
Résumé
Infectious and immunological theories of schizophrenia have been discussed for over a century. Contradictory results for infectious agents in association with schizophrenia spectrum disorders (SSDs) were reported. The rationale of this study was to investigate intrathecal antibody synthesis of the most frequently discussed neurotropic pathogens using a pathogen-specific antibody index (AI) in patients with SSD in comparison to controls. In 100 patients with SSD and 39 mentally healthy controls with idiopathic intracranial hypertension (IIH), antibodies against the herpesviruses EBV, CMV, and HSV 1/2 as well as the protozoan Toxoplasma gondii, were measured in paired cerebrospinal fluid (CSF) and serum samples with ELISA-kits. From these antibody concentrations the pathogen-specific AIs were determined with the assumption of intrathecal antibody synthesis at values > 1.5. No significant difference was detected in the number of SSD patients with elevated pathogen-specific AI compared to the control group. In a subgroup analysis, a significantly higher EBV AI was observed in the group of patients with chronic SSD compared to patients with first-time SSD diagnosis (p = 0.003). In addition, two identified outlier EBV patients showed evidence for polyspecific immune reactions (with more than one increased AI). Evidence for the role of intrathecal EBV antibody synthesis was found in patients with chronic SSD compared to those first diagnosed. Apart from a possible infectious factor in SSD pathophysiology, the evidence for polyspecific immune response in outlier patients may also suggest the involvement of further immunological processes in a small subgroup of SSD patients.
Identifiants
pubmed: 35906648
doi: 10.1186/s12987-022-00355-7
pii: 10.1186/s12987-022-00355-7
pmc: PMC9338642
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Informations de copyright
© 2022. The Author(s).
Références
Br J Psychiatry. 1985 Aug;147:145-9
pubmed: 2994792
Curr Top Behav Neurosci. 2020;44:141-159
pubmed: 30895532
Schizophr Res. 2014 Sep;158(1-3):19-24
pubmed: 25048425
Ethiop Med J. 2011 Jul;49(3):211-20
pubmed: 21991754
Bipolar Disord. 2015 May;17(3):291-302
pubmed: 25109751
Fluids Barriers CNS. 2017 Dec 7;14(1):34
pubmed: 29212505
Transl Psychiatry. 2020 Aug 12;10(1):279
pubmed: 32782247
Science. 1982 May 21;216(4548):892-4
pubmed: 6281883
PLoS One. 2014 Mar 24;9(3):e90203
pubmed: 24662942
Schizophr Bull. 2018 Aug 20;44(5):983-992
pubmed: 29889280
Biol Psychiatry. 2007 May 15;61(10):1215-7
pubmed: 17207471
Fluids Barriers CNS. 2015 Dec 13;12:27
pubmed: 26652013
Schizophr Bull. 2012 May;38(3):642-7
pubmed: 22446566
Schizophr Res. 2021 Feb;228:193-197
pubmed: 33450604
Brain Sci. 2020 Jun 08;10(6):
pubmed: 32521749
NPJ Schizophr. 2015 Nov 04;1:15041
pubmed: 27336045
Biol Psychiatry. 1994 Oct 15;36(8):517-21
pubmed: 7827214
Schizophr Res. 2019 Apr;206:291-299
pubmed: 30478008
Arch Virol. 1981;67(4):333-9
pubmed: 6263228
Eur Arch Psychiatry Clin Neurosci. 2004 Feb;254(1):4-8
pubmed: 14991372
Compr Psychiatry. 2020 Oct;102:152196
pubmed: 32927367
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
Psychiatr Danub. 2016 Jun;28(2):132-8
pubmed: 27287787
Neurology. 2012 Jan 3;78(1):15-23
pubmed: 22156987
J Clin Med. 2020 Jul 27;9(8):
pubmed: 32726952
CNS Drugs. 2006;20(11):879-85
pubmed: 17044725
Schizophr Res. 2021 May;231:205-213
pubmed: 33887648
J Neurol Sci. 2001 Mar 1;184(2):101-22
pubmed: 11239944
PLoS One. 2017 Apr 7;12(4):e0175279
pubmed: 28388676
Schizophr Res. 2019 Jul;209:40-47
pubmed: 30639164
Neurosci Res. 2017 Feb;115:59-63
pubmed: 27856235
Transl Psychiatry. 2021 May 21;11(1):308
pubmed: 34021122
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Schizophr Res. 2010 Sep;122(1-3):257-63
pubmed: 20598509
Schizophr Bull. 2019 Sep 11;45(5):1112-1119
pubmed: 30462333
BMC Infect Dis. 2011 Oct 21;11:281
pubmed: 22018204
N Engl J Med. 2019 Oct 31;381(18):1753-1761
pubmed: 31665579
Br J Psychiatry. 1978 Apr;132:342-8
pubmed: 638387
PLoS Negl Trop Dis. 2017 Nov 6;11(11):e0006040
pubmed: 29108011
Mol Psychiatry. 2008 May;13(5):470-9
pubmed: 18268502
J Neurol. 2018 May;265(5):1106-1114
pubmed: 29511863
Hum Antibodies. 2018 Feb 5;26(2):87-93
pubmed: 29036805
Schizophr Res. 2012 Apr;136(1-3):128-36
pubmed: 22104141
J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):681-686
pubmed: 32371533
Clin Microbiol Infect. 2021 Sep;27(9):1207-1211
pubmed: 33813108
World J Clin Pediatr. 2014 Aug 08;3(3):59-68
pubmed: 25254186
Cureus. 2021 Jun 19;13(6):e15764
pubmed: 34164252
Psychiatry Res. 2020 Sep;291:113157
pubmed: 32593064
Clin Microbiol Rev. 1995 Jan;8(1):131-45
pubmed: 7704891
Lancet Psychiatry. 2020 Jan;7(1):93-108
pubmed: 31669058
Schizophr Res. 2003 Aug 1;62(3):237-44
pubmed: 12837520
Adv Clin Exp Med. 2017 Sep;26(6):1031-1036
pubmed: 29068607
Sci Rep. 2016 Mar 03;6:22551
pubmed: 26936108
Psychol Med. 2013 Feb;43(2):239-57
pubmed: 22717193
PLoS One. 2019 Jul 10;14(7):e0219454
pubmed: 31291336
Mult Scler Relat Disord. 2019 May;30:187-191
pubmed: 30785075
Neurosurg Rev. 2021 Apr;44(2):1183-1189
pubmed: 32458276